Heron Therapeutics, Inc. (HRTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.30+4.88%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · HRTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
HRTX — earnings in line
Dated 2026-08-10
and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: These products grew in Q2 while oncology sales fell. Continued gains can help offset the drop in CINVANTI and SUSTOL sales.
Supportive ifQ3 revenue rises year over year for both ZYNRELEF and APONVIE, from their Q2 levels of $11.1 million and $4.2 million.
Worry ifQ3 year-over-year revenue falls for either product from its Q2 level.
Why it matters: Q2 revenue rose 9% from Q1 but was below management's expectations. A fresh forecast would show whether the company can plan around current risks.
Watch forOn November 9, Q3 revenue tops $37.7 million. Management gives a new full-year revenue forecast.
Also watch forOn November 9, Q3 revenue is under $37.7 million. Management gives no new full-year forecast.
Why it matters: Heron had $42.7 million in cash at Q2 end. The credit deal eased near-term terms, but the next update can show whether cash holds up.
Watch forThe next report shows cash and short-term investments above $42.7 million, with no new debt issue disclosed.
Also watch forThe next report shows cash and short-term investments below $42.7 million, or reports new borrowing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$242 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $790 loss on $10,000 · 7.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,188 loss on $10,000 · 81.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.